Calendar Opportunities Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Biotech Glossary
Embed Widget

Legal

About
ML Track Record
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

⚠️ Not Financial Advice (NFA)

CatalystAlert provides data aggregation and analysis tools only. All probability scores and predictions are based on historical data and are NOT guarantees of future results. Past performance does not indicate future success. We are not responsible for the accuracy of third-party data sources. Always consult a qualified financial advisor before making investment decisions.

© 2025 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

Semaglutide - Phase 3 | NVO Pipeline | CatalystAlert

Semaglutide

Phase 3

Novo Nordisk A/S (NVO)

58%

Phase 3

Development Phase

2

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

Jun 2

NVO⭐Phase 3

Semaglutide Phase 3 Results Expected

Semaglutide • Obesity

Feb 20

NVO⭐Phase 3

Semaglutide Phase 3 Results Expected

Semaglutide • Obesity

Drug Information

Target Indication

Obesity

Clinical Trial

Last updated: 12/7/2025

Developer

NVO

Novo Nordisk A/S

Biotechnology•Europe•NYSE

Related Pipeline

sitagliptinPhase 3

Diabetes

biphasic insulin aspartPhase 3

Diabetes

Semaglutide 1.0 mgPhase 3

Obesity

CagrilintidePhase 3

Obesity or Overweight

biphasic human insulinPhase 3

Diabetes

View full pipeline